Investors are beginning to turn cautious on biotechnology stocks as a rapid rise in Treasury yields dents the appeal for shares of companies that are often viewed as risky all-or-nothing bets on breakthrough medical treatments.
Investors are beginning to turn cautious on biotechnology stocks as a rapid rise in Treasury yields dents the appeal for shares of companies that are often viewed as risky all-or-nothing bets on breakthrough medical treatments.
<iframe src="https://statesidedaily.com/embed/cluster/53c579d32c3dd302e94c5fe1a1cbbfb9e19ed97e" width="100%" height="320" style="border:0;max-width:680px" loading="lazy" title="All-or-Nothing Biotech Bets Dented by Rising Treasury Yields"></iframe>
